Dr. Moss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
725 Welch Rd, suite 350
Palo Alto, CA 94304Phone+1 650-725-8188Fax+1 650-723-5201- Is this information wrong?
Education & Training
- Stanford University1980 - 1981
- Stanford Health Care-Sponsored Stanford UniversityResidency, Allergy and Immunology, 1977 - 1981
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Allergy and Immunology, 1977 - 1979
- McGaw Medical Center of Northwestern UniversityResidency, Pediatrics, 1975 - 1977
- State University of New York Downstate Medical Center College of MedicineClass of 1975
- Columbia UniversityBA, 1971
Certifications & Licensure
- CA State Medical License 1977 - 2025
- American Board of Allergy and Immunology Allergy & Immunology
- American Board of Allergy and Immunology Diagnostic Laboratory Immunology
- American Board of Pediatrics Pediatrics
- National Board of Medical ExaminersMedical Examiners
Awards, Honors, & Recognition
- Invited Plenary Speaker International Society of Human and Animal Mycology, Berlin Germany, 2012
- NIH-NHBLI Special Emphasis Panel Clinical Trials of Novel Therapy for Lung Diseases, 2010
- Who’s Who in America Marquis’ Who’s Who, 2006
- Join now to see all
Clinical Trials
- Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) Start of enrollment: 2012 Jul 01
- Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF) Start of enrollment: 2014 Aug 01
- Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients Start of enrollment: 2015 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Revised clinical practice guidelines for diagnosing, classifying, and treating allergic bronchopulmonary aspergillosis/mycoses: a Delphi statement from the ISHAM-ABPA ...Agarwal, R., Singh Sehgal, I., Muthu, V., Denning, D., Chakrabarti, A., Soundappan, K., Garg, M., Rudramurthy, S., Dhooria, S., Armstrong-James, D., Asano, K., Gangneu...> ;The European Respiratory Journal. 2024 Mar 7
- Correction: Moss, R.B. Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals.2023,, 85.Richard B Moss> ;Journal of Fungi. 2023 Apr 6
- 1 citationsEvaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized...Joseph E Levitt, Haley Hedlin, Sophie Duong, Di Lu, Justin Lee, Bryan Bunning, Nadia Elkarra, Benjamin A Pinsky, Eileen Heffernan, Eric Springman, Richard B Moss, Hect...> ;Clinical Infectious Diseases. 2023 Jul 26
- Join now to see all
Journal Articles
- IgE and IgG antibodies to casein in suspected cow's milk allergy.Leong RE, Moss RB, Blessing J, Cheung NKV, Cheung I, Lewiston NJ, Ann Allergy 50:352
- Humoral immune response to inhaled and parenteral allergens: role of IgG4 antibody in clinical protection.Moss RB, Hsu YP, J Allergy Clin Immunol 73:138
- A quantitative immunoenzymatic assay for allergenspecific IgE antibodies. Comparison with three other in vitro assays.Moss RB, Hsu YP, Kwasnicki M, Reid MJ, Clin Res 32:41A
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Improvement in ion transport biomarkers and spirometry with the investigational CFTR potentiator VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation.SM Rowe SM, FJ Accurso FJ, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewsk JM, Rubenstein R, Uluer AZ, Aitke..., International Congress on Pediatric Pulmonology
- Mechanistic studies of tolerance in sublingual immunotherapy patients with Dermatophagoides farniae and timothy grass allergy.Nguyen H, Hoyte EG, Vissamsetti S, Siva AM, Saper VE, Hwang PH, Moss RB, Nadeau KC, Federation of Clinical Immunology Societies
- Improved CFTR and lung function with VX-770, a novel oral potentiator of CFTR, in subjects with the G551D-CFTR mutation.Donaldson SH, Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML..., European Respiratory Society
- Join now to see all
Lectures
- Current Status of Early Treatment for CF Lung Infection.Montreal Children's Hospital-McGill University, Montreal Canada
- Cystic Fibrosis Quality Care for Quality Outcomes.Children’s Hospital, Columbus
- CF Lung Disease: Is There a Threshold for Intervention?University of Wisconson, Madison WI - 11/10/2005; West Palm Beach FL
- Join now to see all
Other
- BioMedNet Biofeedback Interview.Moss RB, HMS Beagle vol 63
http://news.bmn.com/hmsbeagle/63/notes/biofeed - Cystic fibrosis: new insights and treatments.Moss RB, Hospital Practice 36:25-37
http://www.hosppract.com/issues/2001/01/moss.htm - Gene therapy for cystic fibrosis: the rise and fall of a viral vector.Moss RB, US Respiratory Disease, 40-41
http://www.touchbriefings.com/download.cfm?fileID=9161 - Join now to see all
Press Mentions
- Cystic Fibrosis Newborn Screening Model Is Highly EffectiveFebruary 10th, 2016
Professional Memberships
- Fellow
- Fellow
- Fellow
- Member
- Pediatric Academic SocietyMember
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: